Feasibility of Using Microsoft Kinect to Assess Upper Limb Movement in Type III Spinal Muscular Atrophy Patients.

Although functional rating scales are being used increasingly as primary outcome measures in spinal muscular atrophy (SMA), sensitive and objective assessment of early-stage disease progression and drug efficacy remains challenging. We have developed a game based on the Microsoft Kinect sensor, spec...

Full description

Bibliographic Details
Main Authors: Xing Chen, Juliane Siebourg-Polster, Detlef Wolf, Christian Czech, Ulrike Bonati, Dirk Fischer, Omar Khwaja, Martin Strahm
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5266257?pdf=render
id doaj-064c0dc62a234960a3a91a48089cb6f7
record_format Article
spelling doaj-064c0dc62a234960a3a91a48089cb6f72020-11-25T01:07:23ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01121e017047210.1371/journal.pone.0170472Feasibility of Using Microsoft Kinect to Assess Upper Limb Movement in Type III Spinal Muscular Atrophy Patients.Xing ChenJuliane Siebourg-PolsterDetlef WolfChristian CzechUlrike BonatiDirk FischerOmar KhwajaMartin StrahmAlthough functional rating scales are being used increasingly as primary outcome measures in spinal muscular atrophy (SMA), sensitive and objective assessment of early-stage disease progression and drug efficacy remains challenging. We have developed a game based on the Microsoft Kinect sensor, specifically designed to measure active upper limb movement. An explorative study was conducted to determine the feasibility of this new tool in 18 ambulant SMA type III patients and 19 age- and gender-matched healthy controls. Upper limb movement was analysed elaborately through derived features such as elbow flexion and extension angles, arm lifting angle, velocity and acceleration. No significant differences were found in the active range of motion between ambulant SMA type III patients and controls. Hand velocity was found to be different but further validation is necessary. This study presents an important step in the process of designing and handling digital biomarkers as complementary outcome measures for clinical trials.http://europepmc.org/articles/PMC5266257?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Xing Chen
Juliane Siebourg-Polster
Detlef Wolf
Christian Czech
Ulrike Bonati
Dirk Fischer
Omar Khwaja
Martin Strahm
spellingShingle Xing Chen
Juliane Siebourg-Polster
Detlef Wolf
Christian Czech
Ulrike Bonati
Dirk Fischer
Omar Khwaja
Martin Strahm
Feasibility of Using Microsoft Kinect to Assess Upper Limb Movement in Type III Spinal Muscular Atrophy Patients.
PLoS ONE
author_facet Xing Chen
Juliane Siebourg-Polster
Detlef Wolf
Christian Czech
Ulrike Bonati
Dirk Fischer
Omar Khwaja
Martin Strahm
author_sort Xing Chen
title Feasibility of Using Microsoft Kinect to Assess Upper Limb Movement in Type III Spinal Muscular Atrophy Patients.
title_short Feasibility of Using Microsoft Kinect to Assess Upper Limb Movement in Type III Spinal Muscular Atrophy Patients.
title_full Feasibility of Using Microsoft Kinect to Assess Upper Limb Movement in Type III Spinal Muscular Atrophy Patients.
title_fullStr Feasibility of Using Microsoft Kinect to Assess Upper Limb Movement in Type III Spinal Muscular Atrophy Patients.
title_full_unstemmed Feasibility of Using Microsoft Kinect to Assess Upper Limb Movement in Type III Spinal Muscular Atrophy Patients.
title_sort feasibility of using microsoft kinect to assess upper limb movement in type iii spinal muscular atrophy patients.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2017-01-01
description Although functional rating scales are being used increasingly as primary outcome measures in spinal muscular atrophy (SMA), sensitive and objective assessment of early-stage disease progression and drug efficacy remains challenging. We have developed a game based on the Microsoft Kinect sensor, specifically designed to measure active upper limb movement. An explorative study was conducted to determine the feasibility of this new tool in 18 ambulant SMA type III patients and 19 age- and gender-matched healthy controls. Upper limb movement was analysed elaborately through derived features such as elbow flexion and extension angles, arm lifting angle, velocity and acceleration. No significant differences were found in the active range of motion between ambulant SMA type III patients and controls. Hand velocity was found to be different but further validation is necessary. This study presents an important step in the process of designing and handling digital biomarkers as complementary outcome measures for clinical trials.
url http://europepmc.org/articles/PMC5266257?pdf=render
work_keys_str_mv AT xingchen feasibilityofusingmicrosoftkinecttoassessupperlimbmovementintypeiiispinalmuscularatrophypatients
AT julianesiebourgpolster feasibilityofusingmicrosoftkinecttoassessupperlimbmovementintypeiiispinalmuscularatrophypatients
AT detlefwolf feasibilityofusingmicrosoftkinecttoassessupperlimbmovementintypeiiispinalmuscularatrophypatients
AT christianczech feasibilityofusingmicrosoftkinecttoassessupperlimbmovementintypeiiispinalmuscularatrophypatients
AT ulrikebonati feasibilityofusingmicrosoftkinecttoassessupperlimbmovementintypeiiispinalmuscularatrophypatients
AT dirkfischer feasibilityofusingmicrosoftkinecttoassessupperlimbmovementintypeiiispinalmuscularatrophypatients
AT omarkhwaja feasibilityofusingmicrosoftkinecttoassessupperlimbmovementintypeiiispinalmuscularatrophypatients
AT martinstrahm feasibilityofusingmicrosoftkinecttoassessupperlimbmovementintypeiiispinalmuscularatrophypatients
_version_ 1725187479872471040